Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03032471
Other study ID # 2017_MST_01
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date July 20, 2017
Est. completion date May 6, 2022

Study information

Verified date May 2022
Source Swiss SOS Study Group
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The primary objective of this multicenter observational study is to determine the effect size of the relationship between DCI and neuropsychological impairment 14-28 days and 3 months after aSAH. Secondary objectives are the feasibility to administer and the validity of the MoCA in an intensive care unit setting, as well as the test/retest reliability of the MoCA in patients with acute brain damage in absence of aSAH.


Description:

Background and rationale: Delayed cerebral ischemia (DCI) is the independent most important predictor of neurological disability in survivors following aneurysmal subarachnoid hemorrhage (aSAH). DCI could also be identified as the most important predictor of moderate to severe neuropsychological impairment following aSAH. Only few prospective studies so far specifically analyzed the effect size of the relationship between DCI and neuropsychological impairment, and all studies had a methodological weakness: lack of a baseline neuropsychological assessment before the onset of DCI. In studies analyzing the neuropsychological outcome after aSAH, the Montreal Cognitive Assessment (MoCA) is the most comprehensive, sensitive and specific instrument among the short tests. The MoCA is increasingly used in the aSAH population, while its validity and reliability has only been demonstrated in the normal population or patients suffering from diseases different from aSAH, such as e.g. Parkinson's disease or dementia. Today, neuropsychological examinations find entry into clinical routine for aSAH patients to estimate the need for inpatient rehabilitation. However, the MoCA is often applied to aSAH patients in a busy intensive or intermediate care unit, while it remains largely unknown whether the distraction in such an environment represents a bias to the obtained results. This study therefore evaluates aSAH patients before and after the phase of DCI, as well as three months after aSAH, in order to estimate the impact of DCI on neuropsychological impairment. In addition, the extent and location of cerebral ischemia, as measured with the Alberta Stroke Program Early CT Score (ASPECTS) is correlated with the neuropsychological outcome. Furthermore, the study measures the test/retest reliability of the MoCA, as well as the influence of the intensive care environment on the MoCA results in a randomized fashion in subjects with acute brain damage (and no aSAH). Objectives: The primary objective of this multicenter observational study is to determine the effect size of the relationship between DCI and neuropsychological impairment 14-28 days and 3 months after aSAH. Secondary objectives are the feasibility to administer and the validity of the MoCA in an intensive care unit setting, as well as the test/retest reliability of the MoCA in patients with acute brain damage in absence of aSAH. Outcomes: The primary endpoint is the proportion of patients with or without DCI that show worsening on the MoCA 3 months after the ictus as compared to before the DCI phase by at least two points. Key secondary endpoints for part 1 of the study are: - The proportion of patients with or without DCI that show worsening on the MoCA 14-28 days after the ictus as compared to before the DCI phase by at least two points. - The absolute difference of the MoCA before and after the active phase of DCI in patients with versus without DCI. - The absolute difference of the MoCA before the active phase of DCI and 3 months after aSAH in patients with versus without DCI - The rate of patients with versus without DCI that show cognitive impairment at 14-28 days and 3 months (defined as MoCA < 26 points) - The correlation of neuropsychological outcome with the extent and location of ischemic lesions on brain CT-scan 12-21 days post-SAH, graded by the semi-quantitative ASPECT-grading - Health-related quality of life at 3 months in patients with versus without DCI - Home-time at 3 months in patients with versus without DCI - Death and dependency at 3 months in patients with versus without DCI - The absolute MoCA result, health-related quality of life and home-time at 3 months in patients with versus without hydrocephalus requiring shunting - The absolute MoCA result, health-related quality of life and home-time at 3 months in patients with surgical versus endovascular aneurysm occlusion Key secondary endpoints for part 2 of the study are: - The test/retest reliability of the MoCA in patients with acute brain damage - The influence of the intensive care environment on the MoCA in patients with acute brain damage


Recruitment information / eligibility

Status Terminated
Enrollment 128
Est. completion date May 6, 2022
Est. primary completion date May 6, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: For part 1 of the study: Participants fulfilling all of the following inclusion criteria are eligible for the study: - Consent of the patient or consent of patient's next of kin (plus consent of an independent physician if patient is unable to consent) - Aneurysmal SAH - Age: =18 - Time of aSAH known (IMPORTANT: at least approximated. Time of aSAH refers to the bleed that lead to hospital admission; warning leaks in the patient history are not considered aSAH in this context) - Complete aneurysm occlusion therapy within 48h after aSAH - Glasgow coma scale (GCS) = 13 points at time point 48h - 72h after aSAH - Fluent language skills in either English, German, French, or Italian For part 2 of the study: Participants fulfilling all of the following inclusion criteria are eligible for the study: - Consent of the patient or consent of patient's next of kin (plus consent of an independent physician if patient is unable to consent) - Age: =18 - Acute brain injury that requires a in-patient treatment, e.g. for (surgical) treatment of a brain tumor, a cerebral hemorrhage, a hydrocephalus, stroke, or traumatic brain injury, with stable neurological and general health status - Glasgow coma scale (GCS) = 13 points - Fluent language skills in either English, German, French, or Italian Exclusion Criteria: For part 1 of the study: The presence of any one of the following exclusion criteria will lead to exclusion of the participant: - SAH due to any other cause than aneurysm or structural abnormality of the brain (arterio-venous malformation, dural arterio-venous fistula, cavernous malformation, dissection, tumor, trauma) - Comatose patients or patients with a reduced vigilance of GCS < 13 at time point 48h - 72h after aSAH - No aneurysm occlusion therapy within 48h after aSAH - Clear signs of arterial vasospasm in the initial (CT-)angiography; indicating that aSAH had occurred already several days prior to admission - Neurologic or psychiatric diseases other than aSAH that can potentially influence the test-performance of a patient on the MoCA (e.g., dementia, multiple sclerosis, bipolar disorder) - Foreseeable difficulties in follow-up due to geographic reasons (e.g., patients living abroad) - Patients who are not fluent in English, German, French, or Italian - Patients requiring sedative or other medication that would interfere with the neuropsychological evaluation For part 2 of the study: The presence of any one of the following exclusion criteria will lead to exclusion of the participant: - Instable neurological or general health-status of the patient, that makes a transport of the patient on the ICU or the office for neuropsychological testing impossible - Suspected fluctuation of the neurological condition and the vigilance of the patient between first and second testing - Known psychiatric disease that can potentially influence the test-performance on the MoCA (e.g., dementia, bipolar disorder) - Patients who are not fluent in English, German, French, or Italian - Patients requiring sedative or other medication that would interfere with the neuropsychological evaluation

Study Design


Intervention

Other:
There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.
There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.

Locations

Country Name City State
Switzerland Universitätsklinik für Neurochirurgie, Inselspital Bern Bern
Switzerland Département des Neurosciences cliniques, Service de Neurochirurgie, Hôpitaux Universitaires de Genève Genève
Switzerland Centre Hospitalier Universitaire Vaudois (CHUV) Lausanne Vaud
Switzerland Primario Neurochirurgia, EOC Ospedale Regionale di Lugano - Civico e Italiano Lugano Ticino
Switzerland Klinik für Neurochirurgie, Kantonsspital St. Gallen St.Gallen
Switzerland Klinik für Neurochirurgie, Universitätsspital Zürich Zürich

Sponsors (13)

Lead Sponsor Collaborator
Swiss SOS Study Group Abteilung für Neuropsychologie, Klinik für Neurologie, Kantonsspital St.Gallen, Abteilung für Neuropsychologie, Klinik für Neurologie, Universitätsspital Zürich, Abteilung für Neuropsychologie, Universitätsklinik für Neurologie, Inselspital Bern, Département des Neurosciences cliniques, Service de Neurochirurgie, CHUV, Lausanne, Département des Neurosciences cliniques, Service de Neurochirurgie, Hôpitaux Universitaires de Genève, Département des Neurosciences cliniques, Service de Neurologie, CHUV, Lausanne, Département des Neurosciences cliniques, Service de Neurologie, Hôpitaux Universitaires de Genève, Klinik für Neurochirurgie, Kantonsspital St. Gallen, Klinik für Neurochirurgie, Universitätsspital Zürich, Primario Neurochirurgia, EOC Ospedale Regionale di Lugano - Civico e Italiano, Primario Neurologia, EOC Ospedale Regionale di Lugano - Civico e Italiano, Universitätsklinik für Neurochirurgie, Inselspital Bern

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Other Random number generation Random number generation, as a test of frontal executive functions in patients with acute brain injury will be assessed using the mental dice task by a neuropsychologist not involved in the treatment of the patient. Up to 1 month following acute brain injury
Other Outcomes in patients with hydrocephalus vs. without hydrocephalus Outcomes 1, 2, 3 and 9-12 will be compared between patients that develop or do not develop hydrocephalus up to 3 months after Subarachnoid Hemorrhage. Up to 3 months after Subarachnoid Hemorrhage
Other Outcomes in patiens treated surgically vs. endovascularly (aneurysm occlusion) Outcomes 1, 2, 3 and 9-12 will be compared between patients that are treated surgically or endovascularly up to 3 months after Subarachnoid Hemorrhage. Up to 3 months after Subarachnoid Hemorrhage
Primary Neuropsychological deterioration on the MoCA The primary endpoint is the in-subject difference of the MoCA before (48-72h after aSAH) and after the active phase of DCI (3 months after aSAH) between patients with and without DCI. The MoCA scores will be assessed by a neuropsychologist, not involved in the treatment of the patient and unaware of the patient's study group assignment (DCI vs. non-DCI). 3 months after Subarachnoid Hemorrhage
Secondary Neuropsychological deterioration on the MoCA As for the primary outcome, the MoCA at 14-28 days after aSAH will be assessed by a neuropsychologist, not involved in the treatment of the patient and unaware of the patient's study group assignment (DCI vs. non-DCI) Up to 28 days after Subarachnoid Hemorrhage (directly after the DCI phase)
Secondary Neuropsychological outcome Absolute results of the MoCA at 48-72h, 14-28 days and 3 months in patients that develop and those that do not develop DCI Up to 3 months after Subarachnoid Hemorrhage
Secondary Reliability of the MoCA in patients with acute brain injury Reliability of the MoCA when tested in a (busy) intermediate care (IMC)/intensive care unit (ICU), as compared to the testing in a (quiet) setting in patients with acute brain injury. Up to 1 month following acute brain injury
Secondary Test-retest reliability of the MoCA in patients with acute brain injury Test-retest reliability of the MoCA in patients with acute brain injury, tested two consecutive times with the MoCA (within 36 hours). Up to 1 month following acute brain injury
Secondary Correlation between MoCA and CT-imaging Correlation of the MoCA at 48-72h with the ASPECTS score for ischemic lesions on the CT-scan at 24-72h Up to 72 hours after Subarachnoid Hemorrhage
Secondary Correlation between MoCA and CT-imaging Correlation of the MoCA at 14-28 days with the ASPECTS score for ischemic lesions on the CT-scan at 12-21 days Up to 28 days after Subarachnoid Hemorrhage (directly after the DCI phase)
Secondary Correlation between MoCA and CT-imaging Correlation of the MoCA at 3 months with the ASPECTS score for ischemic lesions on the CT-scan between 6 weeks and 3 months 3 months after Subarachnoid Hemorrhage
Secondary Dependency/Mortality Will be assessed by a neuropsychologist, not involved in the treatment of the patient and unaware of the patient's study group assignment (DCI vs. non-DCI) based on the mRS at 3 months, where modified Rankin Scale (mRS) 4 and 5 is considered as dependency, and mRS 6 is considered dead 3 months after Subarachnoid Hemorrhage
Secondary Health-related quality of life (HRQoL) Will be assessed by a neuropsychologist, not involved in the treatment of the patient and unaware of the patient's study group assignment (DCI vs. non-DCI) using the Euro-Qol (EQ-5D) 3 months after Subarachnoid Hemorrhage
Secondary Shunt dependency (ventriculo-peritoneal or ventriculo-atrial shunt) Will be assessed by a neuropsychologist, not involved in the treatment of the patient and unaware of the patient's study group assignment (DCI vs. non-DCI) 3 months after Subarachnoid Hemorrhage
Secondary Home time Length of time (in days) spent in own home or relative's home since Subarachnoid Hemorrhage. Will be assessed by a neuropsychologist, not involved in the treatment of the patient and unaware of the patient's study group assignment (DCI vs. non-DCI) 3 months after Subarachnoid Hemorrhage
Secondary Minimum Clinically Important Difference (MCID) of the MoCA The MCID in patients with aneurysmal Subarachnoid Hemorrhage is determined using three different anchor-based approaches (using the GCS and NIHSS as anchors), namely the average change approach, minimum detectable change approach, and the change difference approach. Up to 3 months after Subarachnoid Hemorrhage
See also
  Status Clinical Trial Phase
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Recruiting NCT03869138 - Alternative Therapies for Improving Physical Function in Individuals With Stroke N/A
Completed NCT04034069 - Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial N/A
Completed NCT04101695 - Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Completed NCT00391378 - Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS) N/A
Recruiting NCT06204744 - Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial N/A
Active, not recruiting NCT06043167 - Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
Active, not recruiting NCT04535479 - Dry Needling for Spasticity in Stroke N/A
Completed NCT03985761 - Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke N/A
Recruiting NCT00859885 - International PFO Consortium N/A
Recruiting NCT06034119 - Effects of Voluntary Adjustments During Walking in Participants Post-stroke N/A
Completed NCT03622411 - Tablet-based Aphasia Therapy in the Chronic Phase N/A
Completed NCT01662960 - Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke N/A
Recruiting NCT05854485 - Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke N/A
Active, not recruiting NCT05520528 - Impact of Group Participation on Adults With Aphasia N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Completed NCT05805748 - Serious Game Therapy in Neglect Patients N/A
Recruiting NCT05621980 - Finger Movement Training After Stroke N/A